# Wolverine (BPC-157 + TB-500): Research Overview — Pro Peptide Strip > A literature summary of the Wolverine two-peptide research blend — BPC-157 and TB-500 — covering the complementary mechanism rationale, the evidence for each component, and why no controlled combination study exists. BPC-157 (angiogenesis via VEGFR2) and TB-500 (cell migration via actin sequestration) — each component well-characterized; the pairing never tested in a controlled trial. ## The short version Wolverine is a research-community two-peptide blend pairing **BPC-157** (Body Protection Compound 157, a 15-amino-acid gastric peptide) with **TB-500** (Ac-LKKTETQ, the actin-binding fragment of thymosin beta-4). The mechanistic rationale is that BPC-157 supplies a local cytoprotective and pro-angiogenic signal via VEGFR2 [10], while TB-500 supplies an intracellular actin-sequestration signal that underlies cell migration, re-epithelialization and progenitor mobilization [11]. Two different pathways, one described as complementary. The operative constraint: no peer-reviewed study has been published that defines a synergy ratio, dose or endpoint for these two peptides given together [8]. A 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only 1 human, "no clinical safety data" — makes no mention of TB-500 or combination use [8]. Both constituents are unapproved; both are WADA-prohibited. This page reports the component evidence and the blend's documented limitations. It does not recommend a dose or a use. ## What it is Wolverine is not a single chemical entity. It is a co-formulated pairing of two distinct synthetic peptides. **BPC-157**: a 15-amino-acid pentadecapeptide with sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (C62H98N16O22, ~1419.5 Da), derived from a partial sequence of Body Protection Compound found in human gastric juice. **TB-500**: a synthetic N-acetylated heptapeptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ; C38H68N10O14, ~889.0 Da), corresponding to residues 17-23 — the actin-binding motif — of the endogenous 43-residue protein Thymosin Beta-4 (Tβ4, ~4963 Da). The blend has no single molecular weight, CAS number or structure; the values above describe the two constituents individually. Fixed-ratio research vials typically combine equal masses of each component. ## How it works The Wolverine blend is rationalized as a two-mechanism pairing. **BPC-157** supplies a local cytoprotective and pro-angiogenic signal: it upregulates and internalizes the VEGFR2 receptor, switching on the VEGFR2-Akt-eNOS pathway downstream, which drives new vessel formation and accelerates blood-flow recovery in ischemic muscle [10]. Additional reported routes include FAK-paxillin (cell migration) and growth-hormone-receptor sensitization in tendon fibroblasts. **TB-500** (and more robustly, full-length thymosin beta-4) supplies an intracellular actin-sequestration signal: the LKKTETQ motif binds monomeric G-actin 1:1, capping both ends of the monomer and regulating the pool of unpolymerized actin that governs cytoskeletal dynamics, cell migration and wound-closure kinetics [11]. In injury models, Tβ4 is associated with accelerated cell migration, angiogenesis, anti-inflammatory and anti-apoptotic signaling, and reduced scar-forming myofibroblast activity [11]. The synergy argument is that angiogenesis (BPC-157) and cell migration (TB-500/Tβ4) are largely non-overlapping steps of the same repair cascade. The synergy claim is a theoretical extrapolation — no controlled head-to-head or combination study has defined a synergistic dose, ratio or endpoint for these two peptides given together. ## What the research shows *Regulatory and safety framing.* A 2026 Sports Medicine narrative review covering BPC-157 and TB-500/thymosin beta-4 among unapproved musculoskeletal peptides concluded that many such peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, the potential for serious harm exists, and these compounds operate largely outside regulatory oversight [1]. *Evidence gap for the combination.* A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies — 35 preclinical, only 1 human — found "no clinical safety data," and concluded evidence is level IV-V (lowest tiers). It makes no mention of TB-500 or any combination; this absence is itself evidence that no controlled Wolverine combination study exists [8]. *Human evidence for BPC-157.* A 2025 narrative review states that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and recommends treating it as investigational [9]. *BPC-157 angiogenesis mechanism.* BPC-157 upregulates VEGFR2 expression and promotes VEGFR2 internalization with downstream VEGFR2-Akt-eNOS pathway activation, increasing vessel density in chick membrane and rat hindlimb ischemia models and accelerating blood-flow recovery; effects were blocked by endocytosis inhibition [10]. *Thymosin beta-4 mechanism.* A multi-model review consolidated thymosin beta-4's actin-binding, pro-migratory, anti-scarring, anti-inflammatory and angiogenic activities as the rationale for clinical development in dermal wounds, corneal injury, and heart and CNS repair [11]. Note: this literature addresses full-length Tβ4, not the TB-500 fragment. ## Reported effects, cautions & safety No community-anecdote signals are compiled in this desk's source material for the Wolverine blend specifically. The following cautions come from the cited literature. - *No controlled combination study.* No peer-reviewed study has defined a synergy ratio, dose or endpoint for BPC-157 and TB-500 given together. The 2025 HSS Journal systematic review of BPC-157 (36 studies, 1 human, "no clinical safety data") makes no mention of TB-500 or combination use [8]. - *TB-500 identity caveat.* "TB-500" as sold is the Ac-LKKTETQ heptapeptide (~889 Da), but the overwhelming majority of efficacy data attributed to it were generated with full-length thymosin beta-4 (~4963 Da) [8]. Wolverine marketing borrows full-length Tβ4 data for one of its two components. - *Preclinical-dominant evidence.* BPC-157 has only three small human pilots; the TB-500 fragment has zero completed controlled human trials (human Tβ4 data are for the full-length protein). The combination's human efficacy and safety are entirely unproven [8][9]. - *Tumor / angiogenesis signal.* Thymosin beta-4 is overexpressed in several cancers and implicated in tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a concern compounded when two pro-repair peptides are combined [11]. - *WADA prohibition.* Both BPC-157 (S0, non-approved substances) and TB-500/thymosin beta-4 (S2, peptide hormones/growth factors) are prohibited by the World Anti-Doping Agency, banned in and out of competition [1][8]. - *Non-regulated supply.* Both constituents are distributed through non-regulated channels; product identity, purity and the actual ratio are unverified outside formal studies. ## Where it fits in recovery research Among the four entries on this desk, Wolverine sits between the full four-component [KLOW](/klow) blend and the two standalone singles. Its two-mechanism rationale — angiogenesis plus cell migration — is arguably the tightest mechanistic argument for combining peptides on this desk, but it still lacks any controlled combination evidence [8]. [BPC-157](/bpc-157) and [TB-500](/tb-500) each have their own pages covering the single-component literature in more depth. See the [comparison page](/compare) for how all four line up. ![Wolverine BPC-157 and TB-500 blend abstract tissue-repair illustration](/images/wolverine.webp) --- A clinical literature briefing on research peptides — peer-reviewed citations, no products, no prescriptions.